🇺🇸 FDA
Patent

US 11787771

Hydrazide containing nuclear transport modulators and uses thereof

granted A61KA61K31/4196A61K31/4439

Quick answer

US patent 11787771 (Hydrazide containing nuclear transport modulators and uses thereof) held by Karyopharm Therapeutics Inc. expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Karyopharm Therapeutics Inc.
Grant date
Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/4196, A61K31/4439, A61K31/454, A61K31/496